- https://doi.org/10.3760/cma.j.cn114015-20210702-00739
Coronavirus disease 2019 vaccination in patients with chronic kidney diseases
Translate Article 
Take Notes Patients with chronic kidney disease (CKD) are at high risk for coronavirus disease 2019 (COVID-19). Government agencies or learned societies in many countries recommend prioritizing patients with CKD for COVID-19 vaccines. The immune response rate to the COVID-19 vaccines is lower in hemodialysis patients and kidney transplant recipients compared with that in healthy individuals, and increasing the number of vaccinations each member of these population may improve their immune response rate. There was no significant difference in the incidence of adverse reactions after vaccination between patients with CKD and healthy controls. Patients with stable CKD should be vaccinated against COVID-19 unless there were contraindications to vaccination. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are all safe for patients with CKD. Patients with CKD treated with rituximab or high-dose glucocorticoid need to weigh the benefits and risks before vaccination, and COVID-19 vaccines can be given when rituximab treatment ends for more than 6 months or after glucocorticoid reduction. Copyright © 2021 by the Chinese Medical Association.
- Research Article
66 - 10.1016/j.ekir.2021.02.011
- Feb 9, 2021
- Kidney International Reports
Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease
- Research Article
- 1
- 10.1016/j.amj.2022.02.007
- Mar 17, 2022
- Air Medical Journal
Vaccination
- Front Matter
- 4
- 10.1016/j.fertnstert.2021.05.083
- May 14, 2021
- Fertility and Sterility
Should women undergoing in vitro fertilization treatment or who are in the first trimester of pregnancy be vaccinated immediately against COVID-19
- Research Article
- 20
- 10.1016/j.kint.2022.07.018
- Aug 11, 2022
- Kidney International
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
- Research Article
- 10.3760/cma.j.cn114015-20210709-00772
- Jan 1, 2021
- Adverse Drug Reactions Journal
Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals. Copyright © 2021 by the Chinese Medical Association.
- Research Article
- 35
- 10.1053/j.gastro.2021.11.001
- Nov 7, 2021
- Gastroenterology
Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients
- Discussion
- 19
- 10.1016/j.jns.2021.120102
- Dec 20, 2021
- Journal of the Neurological Sciences
Acute transverse myelitis after BNT162b2 vaccination against COVID-19: Report of a fatal case and review of the literature
- Research Article
- 3
- 10.1016/j.jgo.2022.07.005
- Jul 15, 2022
- Journal of Geriatric Oncology
Updated International Society of Geriatric Oncology COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer
- Discussion
- 43
- 10.1016/j.kint.2021.04.010
- Apr 20, 2021
- Kidney International
Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won
- Research Article
- 23
- 10.1016/j.molmed.2022.04.012
- May 3, 2022
- Trends in molecular medicine
COVID-19 vaccines in pregnancy.
- Discussion
- 10.1016/j.jaip.2021.03.016
- Jun 1, 2021
- The Journal of Allergy and Clinical Immunology: In Practice
Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
- Front Matter
- 34
- 10.1016/j.jaip.2021.01.022
- Jan 30, 2021
- The Journal of Allergy and Clinical Immunology. in Practice
The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World
- Front Matter
- 104
- 10.1053/j.ajkd.2021.06.004
- Jun 25, 2021
- American Journal of Kidney Diseases
De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?
- Discussion
- 61
- 10.1016/j.kint.2021.08.017
- Aug 30, 2021
- Kidney International
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
- Discussion
- 10.1016/j.ejim.2023.06.014
- Jun 16, 2023
- European Journal of Internal Medicine
Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?